do not combine dpp-4 inhibitors with glp-1 receptor agonists guidance Therapeutic Effects of and in Neuropathic Pain: Mechanisms and Clinical Implications Safety of SGLT2 inhibitors, DPP-4

SARS-CoV-2 infection generates massive ROS production and the excessive oxidative damage is responsible for cytokine storm, undermined immunity, tissue damage and severe lung disease causing ARDS and death (Silvagno et al., 2020)

Overall, exploration of the pharmacological properties of NO-releasing agents, optimization of their delivery systems, and evaluation of their long-term safety and efficacy will be key directions in future studies

This is likely to become a less salient issue as drug developers develop new formulations with more convenient dosing routes and schedules since overall simpler dosing (fewer steps, less frequent dosing) tends to improve medication satisfaction and adherence (Rodriguez et al., 2025)

You can also reference this fact sheet from WADA for more information